Journal profile · Biotechnology & Applied Microbiology
Pharmacogenetics and Genomics
ISSN 1744-6872 · eISSN 1744-6880 · Lippincott Williams and Wilkins Ltd. · UNITED STATES · Monthly · Founded 2005
Pharmacogenetics and Genomics: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.6; JCR Q4 (journal website); hybrid open access; median 99 days to acceptance (35 articles, last 24 months); community-reported acceptance: about 5%; 32 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Pharmacogenetics and Genomics is published by Lippincott Williams and Wilkins Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms and Genetic Associations and Epidemiology, together about 40.7% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Gastroesophageal reflux disease is primarily treated with proton pump inhibitors (PPIs), which are metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. CYP2C19 polymorphisms affect PPI plasma levels, with rapid (2–27%) and ultra-rapid (<1–5%) metabolizers needing higher doses, while poor (3–15%) and intermediate (27–47%) metabolizers require lower doses for therapeutic effectiveness. Antireflux surgery is recommended for patients refractory to medical therapy or with symptomatic hiatal hernias.
From the journal's Aims & Scope
Research area (LetPub): Biotechnology & Applied Microbiology
Editor-in-chief M. SchwabPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics24.2%
- Drug Transport and Resistance MechanismsMedicine10.5%
- Genetic Associations and EpidemiologyBiochemistry, Genetics and Molecular Biology6%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience4.8%
- Glutathione Transferases and PolymorphismsBiochemistry, Genetics and Molecular Biology4.4%
- Eicosanoids and Hypertension PharmacologyBiochemistry, Genetics and Molecular Biology3.5%
- Acute Lymphoblastic Leukemia researchMedicine3.4%
- HIV/AIDS drug development and treatmentMedicine3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biotechnology & Applied Microbiology | Zone 4 |
| Minor | Genetics & Heredity | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Genetics & Heredity | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q4 · BIOTECHNOLOGY & APPLIED MICROBIOLOGY · rank 155/180
- JCR Q4 · GENETICS & HEREDITY · rank 151/192
- JCR Q4 · PHARMACOLOGY & PHARMACY · rank 276/356
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.6LetPub ·
- Impact factor (publisher)
- 1.6Publisher website ·
- CiteScore 2026-06
- 3.2LetPub ·
- SJR 2026-06
- 0.5LetPub ·
- SNIP 2026-06
- 0.67LetPub ·
- h-index
- 134LetPub ·
- h-index
- 112OpenAlex ·
- i10-index
- 1,205OpenAlex ·
- 2-year mean citedness
- 1.99OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 11.76%LetPub ·
Volume
- Articles per year
- 25LetPub ·
Articles by year OpenAlex count · 1,618 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 29 | 8 | 2 |
| 2025 | 32 | 7 | 42 |
| 2024 | 37 | 11 | 151 |
| 2023 | 30 | 9 | 147 |
| 2022 | 27 | 7 | 199 |
| 2021 | 37 | 17 | 405 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
99 daysMedian, submission to acceptance · P25–P75 67 days – 145 days
- Acceptance to online
- median 42 days (35 articles)
- Submission to online
- median 148 days
- Sample
- 35 articles with submission and acceptance dates (71 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 5%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lippincott Williams and Wilkins Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 2005
- ISSN
- 1744-6872
- Electronic ISSN
- 1744-6880
- Latest issue on the website
- Volume 36, Issue 5 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Pharmacogenetics and Genomics
What CAS zone is Pharmacogenetics and Genomics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pharmacogenetics and Genomics is in Zone 4 of Medicine, and in Zone 4 of the minor category Biotechnology & Applied Microbiology / Genetics & Heredity / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Pharmacogenetics and Genomics?
The latest impact factor listed by LetPub is 1.6; CiteScore 3.2, h-index 112.
How long does peer review take at Pharmacogenetics and Genomics?
Based on the dates recorded on 35 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 99 days (interquartile range 67–145 days); authors report an average review time of about 3 months; the community-reported acceptance is “about 5%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Pharmacogenetics and Genomics in?
The journal's website gives JCR Q4; by category, BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q4 (155/180), GENETICS & HEREDITY Q4 (151/192), PHARMACOLOGY & PHARMACY Q4 (276/356). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Pharmacogenetics and Genomics?
According to LetPub and DOAJ records, Pharmacogenetics and Genomics is indexed in SCIE and Scopus.
Is Pharmacogenetics and Genomics open access, and what is the APC?
Pharmacogenetics and Genomics is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .